NeoGenomics, Inc. (NEO)

NeoGenomics' stock has been impacted by its earnings reports. In the third quarter of 2025, the company reported a 12% year-over-year increase in consolidated revenue, surpassing expectations, but the net loss increased by 53%. Earlier, in the fourth quarter of 2024, NeoGenomics missed revenue expectations, though sales still rose. The stock price as of October 22, 2025, was $10.34 per share, representing a decline of 20.93% from October 23, 2024.

While specific information on the seasonality of demand for NeoGenomics' oncology diagnostic products and services is not explicitly detailed, the company's performance can be influenced by the unpredictability in pharma and biotech demand and competition within the oncology diagnostics sector. This suggests that demand may fluctuate rather than follow a strict seasonal pattern.

NeoGenomics, Inc. is a leading provider of oncology diagnostic solutions, focusing on precision medicine. The company offers over 500 advanced tests, including genetic analysis, molecular testing, and next-generation sequencing. NGS testing has shown significant growth, accounting for nearly one-third of its clinical revenue.

NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories across the United States and the United Kingdom. The company's global headquarters is located in Fort Myers, Florida.

NeoGenomics Laboratories received the Elevate Award at the 2025 Industry Appreciation Awards in October 2025. This award recognized the company for demonstrating exceptional growth and embodying values that strengthen the broader business community.

NeoGenomics has a diverse ownership structure, with a significant portion held by institutional investors such as BlackRock, Inc. and Vanguard Group Inc. Institutional investors collectively hold approximately 30.24% to 54.76% of the company's stock, while insiders own about 1.23%, and public companies and individual investors hold around 24.52% to 44.02%.